Buy these 2 impressive ASX shares in March 2022: experts

These two ASX shares are ones that experts believe investors should buy next month.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Experts rate these two impressive ASX shares as good looking investment candidates in March 2022
  • Bubs is a rapidly-growing infant formula business with global growth aspirations
  • ELMO is a software business with a strong presence in both Australia and the UK

Experts have rated some ASX shares as impressive opportunities in March 2022.

These are businesses with long-term growth plans and management teams motivated to achieve those goals.

Whilst brokers don't always get everything right, they like to keep a keen eye on business valuations to find ideas.

These are two ASX shares that experts like right now:

A stopwatch ticking close to the 12 where the words on the face say 'Time to Buy'.

Image source: Getty Images

Bubs Australia Ltd (ASX: BUB)

Bubs is one of the leading Australian infant formula companies currently seeing a lot of growth with plans for a lot more.

Citi rates Bubs as a buy with a price target of $0.73 – that's around 70% higher than where it is today.

The broker pointed to several positives from the Bubs half-year result, including US distribution expansion and Australia's international borders opening up, providing a tailwind to sales.

In the first six months of FY22, Bubs reported positive underlying earnings before interest, tax, depreciation and amortisation (EBITDA) of $1.2 million, after 84% year-on-year growth of group revenue to $33.6 million. There was also a "significant improvement" in the gross profit margin to 38%.

One of the key highlights was that the ASX share's corporate daigou gross revenue was at a record high, exceeding pre-COVID levels, rising by 276%. There was also 53% growth of Chinese cross-border e-commerce gross revenue.

Bubs revealed that it's now listed with the three largest US national food distributors. It has also secured ranging at Southern California's largest food retailer.

Citi thinks that Bubs could start making a positive net profit after tax (NPAT) in FY23.

ELMO Software Ltd (ASX: ELO)

ELMO is a provider of HR and payroll software to small and medium businesses in Australia and the UK.

Morgan Stanley currently rates the share as a buy with a price target of $7.80. That suggests a possible upside of around 110% over the next year, if the broker ends up being right.

The first half of FY22 showed a significant growth for the business and it increased its FY22 guidance, but that seemingly wasn't enough for the market to be positive about the result.

ELMO said that annualised recurring revenue (ARR) of $98.3 million was an increase of 35% compared to 30 June 2021. Revenue rose by 41% to $43.1 million.

The ASX share generated a positive earnings before interest, tax, depreciation and amortisation (EBITDA). Half-year EBITDA rose by $0.9 million to $0.3 million. ARR guidance was increased to a range of $107 million to $113 million for FY22.

ELMO revealed that operating leverage continues to improve with a reduction in key spending ratios across the business. This has driven the positive EBITDA result and reduced the monthly operating cash burn by 36%.

The company launches new modules to make itself more useful for clients and increase the possible value of each client to ELMO, if they sign up. This can make the client even more sticky as well.

Management also noted that the UK acquisitions are performing "exceptionally well" and provide a solid foundation to increase its market share in the region.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Elmo Software. The Motley Fool Australia owns and has recommended Elmo Software. The Motley Fool Australia has recommended BUBS AUST FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Teen standing in a city street smiling and throwing sparkling gold glitter into the air.
Broker Notes

9 ASX shares just upgraded by the experts

Several ASX 200 gold miners are in the mix.

Read more »

A guys points his fingers down.
Broker Notes

6 ASX shares downgraded by brokers this week

Brokers cut their ratings on Elders, Charter Hall Retail REIT, Sims, and other stocks this week. 

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

Morgans says these ASX shares could return 48% to 95%

The broker is recommending these shares to investors this week.

Read more »

Farmer holding grains in his hands.
Broker Notes

Why this broker thinks GrainCorp shares are a buy after yesterday's fall

This broker is expecting a rebound.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

ASX healthcare shares are 39% higher since June. Are you missing out?

Healthcare stocks endured a long slump before the sector pivoted three months ago.

Read more »

Six smiling office colleagues stand in a row and look at the camera.
Broker Notes

9 ASX 200 shares earning strengthened buy ratings this week

Brokers retained a positive view on Santos, Goodman, AMP, Telstra, and other shares this week. 

Read more »

A middle-aged man working from home looks at his mobile phone with a laptop open on the table in front of him.
Broker Notes

Buy, hold, sell: Select Harvests, Seek, SKS Technologies shares

Experts reveal their ratings on 3 ASX shares in the agriculture, communications, and tech segments. 

Read more »

A young man working from home sits at his home office desk holding a cup of tea and looking out the window.
Broker Notes

Buy, hold, sell: Generation Development, Fletcher Building, Saluda Medical shares

We review 3 fresh buy, hold, and sell calls from expert market analysts. 

Read more »